Arcus Capital Lease Obligations from 2010 to 2025
| RCUS Stock | USD 8.49 0.23 2.78% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 12 M | Current Value 11.4 M | Quarterly Volatility 26 M |
Check Arcus Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcus Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 50.4 M, Interest Income of 54.6 M or Depreciation And Amortization of 6.7 M, as well as many indicators such as Price To Sales Ratio of 4.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. Arcus financial statements analysis is a perfect complement when working with Arcus Biosciences Valuation or Volatility modules.
Arcus | Capital Lease Obligations |
Latest Arcus Biosciences' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Arcus Biosciences over the last few years. Arcus Biosciences capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Arcus Biosciences asset purchases. For example, Arcus Biosciences can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Arcus Biosciences control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Arcus Biosciences' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcus Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Arcus Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 20,122,500 | |
| Geometric Mean | 14,825,482 | |
| Coefficient Of Variation | 129.23 | |
| Mean Deviation | 12,095,562 | |
| Median | 15,243,000 | |
| Standard Deviation | 26,004,782 | |
| Sample Variance | 676.2T | |
| Range | 113.9M | |
| R-Value | 0.12 | |
| Mean Square Error | 713.7T | |
| R-Squared | 0.01 | |
| Significance | 0.65 | |
| Slope | 668,888 | |
| Total Sum of Squares | 10143.7T |
Arcus Capital Lease Obligations History
About Arcus Biosciences Financial Statements
Arcus Biosciences shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Arcus Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Arcus Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcus Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 12 M | 11.4 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.